" /> Fanconi anemia, complementation group a - CISMeF





Preferred Label : Fanconi anemia, complementation group a;

Symbol : FANCA;

CISMeF acronym : FA; FANCA;

Type : Phenotype, molecular basis known;

Alternative titles and symbols : Fanconi anemia; FA;

Included titles and symbols : Fanconi anemia, estren-dameshek variant; Estren-dameshek variant of fanconi anemia; Estren-dameshek variant of fanconi pancytopenia;

Description : Fanconi anemia is a clinically and genetically heterogeneous disorder that causes genomic instability. Characteristic clinical features include developmental abnormalities in major organ systems, early-onset bone marrow failure, and a high predisposition to cancer. The cellular hallmark of FA is hypersensitivity to DNA crosslinking agents and high frequency of chromosomal aberrations pointing to a defect in DNA repair (summary by Deakyne and Mazin, 2011). Soulier et al. (2005) noted that the FANCA, -C, -E, -F, -G, and -L proteins are part of a nuclear multiprotein core complex which triggers activating monoubiquitination of the FANCD2 protein during S phase of the growth cycle and after exposure to DNA crosslinking agents. The FA/BRCA pathway is involved in the repair of DNA damage. Some cases of Fanconi anemia have presented with a VACTERL (192350) or;

Inheritance : Autosomal recessive;

Molecular basis : Caused by mutation in the Fanconi anemia, complementation group A gene (FANCA, 607139.0001);

Laboratory abnormalities : Multiple chromosomal breaks; Chromosomal breakage induced by diepoxybutane (DEB), and mitomycin C; Deficient excision of UV-induced pyrimidine dimers in DNA; Prolonged G2 phase of cell cycle;

Prefixed ID : #227650;

Details


You can consult :


Nous contacter.
11/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.